BLIS Technologies Limited
7
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Colonisation of Scalp by Topical Probiotic Micrococcus Luteus Q24
Role: lead
Colonization of Skin by M. Luteus Q24 Probiotic
Role: lead
Probiotic Toothpaste to Assess Microbial Colonization
Role: lead
Assessment of Colonisation and Skin Quality Parameter Improvement by Probiotic Micrococcus Luteus Q24 Balm in Healthy Adults.
Role: lead
Colonisation Efficacy of a Probiotic Chewing Gum.
Role: lead
Microbial Colonization of Oral Probiotics
Role: lead
Colonisation Efficacy of Oral Probiotic Fast Melt Powder
Role: lead
All 7 trials loaded